Facebook
Twitter
LinkedIn
Forward
Obesity pharmacotherapy often is solely equated as therapeutic use of anti-obesity medications (AOMs). In this session, two important factors in obesity pharmacotherapy will be discussed.
|
This talk will review key features of obesity pathogenesis related to genetics, the brain, and energetics.
|
This session will review the relationship and underlying mechanisms between obesity and cardiovascular disease with attention to the individual variability between BMI and CV risk.
|
The body mass index (BMI) is the most commonly used screening tool for obesity. However, the BMI is a population-based tool with several limitations when applied to individuals.
|
This session will examine the use of on-label anti-obesity pharmacotherapy to treat obesity.
|
Join Dr. Carolynn Francavilla and Stephanie Burke, both level 1 CrossFit Coaches, in this session where we look past BMI and see the inner athlete in everyone.
|
OMA 2023 Spring Summit: Do Sleepy Brains Make Poor Food & Other Lifestyle Choices? Impact of Sleep on Weight Management (On Demand)CME/CE Expiration Date: 4/23/26
|
Obesity with sarcopenia poses a dual health concern especially in aging populations.
|
We are at a unique place in obesity care history where anti-obesity medications (AOMs) are showing promising, clinically significant weight loss for persons with obesity.
|
Social determinants of health, the conditions in the environments where people are born, live, learn, work, play, worship, and age, play a large role in how well patients can adhere to weight manag
|